Tom Fuchs, Cimeio Therapeutics CEO
June 22, 2023 11:28 AM EDTUpdated 07:00 PM
Deals
Cell/Gene Tx

Cor­rect­ed: Prime Med­i­cine part­ners with Ver­sant-backed biotech to de­vel­op safer stem cell trans­plants

Lei Lei Wu

News Reporter

Prime Med­i­cine and Cimeio Ther­a­peu­tics are part­ner­ing to de­vel­op gene-edit­ed stem cell treat­ments for two kinds of bone mar­row can­cers and oth­er po­ten­tial ge­net­ic dis­eases …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Up­stream Bio files for IPO in sign of life for biotech pub­lic of­fer­ings

Tang Cap­i­tal’s Con­cen­tra bids for Sin­gu­lar Ge­nomics days af­ter Deer­field of­fer

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times